BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 10561351)

  • 1. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
    Yung WK; Prados MD; Yaya-Tur R; Rosenfeld SS; Brada M; Friedman HS; Albright R; Olson J; Chang SM; O'Neill AM; Friedman AH; Bruner J; Yue N; Dugan M; Zaknoen S; Levin VA
    J Clin Oncol; 1999 Sep; 17(9):2762-71. PubMed ID: 10561351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
    Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F
    J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
    Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
    Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
    Nishikawa R; Shibui S; Maruno M; Sugiyama K; Sato S; Fujimaki T; Takahashi H; Wakabayashi T; Takahashi J; Kochi M; Nakamura H; Sawamura Y; Ikeda J; Hori T; Aoki T; Matsutani M
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1279-85. PubMed ID: 16969025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
    Chamberlain MC; Tsao-Wei DD; Groshen S
    Cancer; 2006 Jan; 106(1):172-9. PubMed ID: 16323194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
    Neyns B; Chaskis C; Joosens E; Menten J; D'Hondt L; Branle F; Sadones J; Michotte A
    Cancer Invest; 2008; 26(3):269-77. PubMed ID: 18317968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
    Chan DT; Poon WS; Chan YL; Ng HK
    Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
    Chamberlain MC; Wei-Tsao DD; Blumenthal DT; Glantz MJ
    Cancer; 2008 May; 112(9):2038-45. PubMed ID: 18361434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma].
    Sun J; Yang XJ; Yang SY
    Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(3):165-8. PubMed ID: 23570586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
    Wick W; Platten M; Meisner C; Felsberg J; Tabatabai G; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Combs SE; Vesper J; Braun C; Meixensberger J; Ketter R; Mayer-Steinacker R; Reifenberger G; Weller M;
    Lancet Oncol; 2012 Jul; 13(7):707-15. PubMed ID: 22578793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
    Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
    Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
    Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
    Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Favourable result for temozolomide in recurrent high-grade glioma].
    Taal W; van der Rijt CD; Sillevis Smitt PA; Kros JM; van Heuvel I; Enting RH; van den Bent MJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1393-9. PubMed ID: 15997692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
    Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
    Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
    Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
    J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.